BioWorld MedTech

Sep. 6, 2016

After selling med-tech arm, Toshiba plans next-gen radiation therapy

TOKYO – Toshiba Corp. is developing a treatment for cancer that uses particle beams and will send the technology to trial next year, aiming to have a device on the market by the early 2020s. Read More

Senators make a push for incorporation of unique device identifiers into insurance claims forms

FDA hits Tosoh with third warning for U.S. operations since 2005

Ultrasound mobility device for the blind generating good vibrations in Canada

Other news to note

Appointments and advancements

Daily M&A

Financings

MDD's Cardiology Extra

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...